<PAGE> 1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM 8-K
CURRENT REPORT,
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):October 1, 1997
(October 6, 1997)
NU-TECH BIO-MED, INC.
(Exact Name of Registrant as Specified in Charter)
DELAWARE 0-11772 25-1411971
--------------- ------------------------ -------------------
(State or Other (Commission File Number) (I.R.S. Employer
Jurisdiction Identification No.)
of Incorporation)
55 ACCESS ROAD
WARWICK, RHODE ISLAND 02886
---------------------- ----------
(Address of Principal (Zip Code)
Executive Offices)
Registrant's telephone number, including area code: (401) 732-6520
----------------------
================================================================================
<PAGE> 2
Item 5. Other Events.
------------
On October 1, 1997, the pending acquisition by the Registrant of a 52%
interest in Physicians Clinical Laboratory, Inc. ("PCL") was completed and PCL
has emerged from its Chapter 11 proceeding.
Pending the preparation and filing by the Registrant of additional reports
with the Securities and Exchange Commission relating to the completion of the
acquisition of its majority interest in PCL, and the Registrant amending its
Selling Shareholder Registration Statements to reflect the completion of the PCL
transaction, all sales by selling shareholders under such Registration
Statements are suspended by the Registrant, and such sales may resume only upon
notification by the Registrant to the selling shareholders that such filings
have been completed.
-2-
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report on Form 8-K to be signed on its behalf by
the undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. MARVIN FEIGENBAUM
----------------------------------------------
Name: J. Marvin Feigenbaum
Title: Chairman of the Board, President, Chief
Executive and Chief Financial Officer
Date: October 6, 1997
-3-